🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

BCDA BCDA

Company Profile ↓
$0.95
-51.53% 1Y
52W High$2.27
52W Low$0.77

Company Overview

BCDA (BCDA) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.

Recent Developments

  • Trailing 12 Months Year-on-year growth — revenue -100.0%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-
1 Year:-100.00%

Stock Price Performance

1 Year:-51.53%
6 Months:-18.10%
3 Months:-13.64%
1 Month:-6.86%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 12% of range
$0.77 $2.27
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMABelow
  • RSI (14)55.05 · Neutral
Price Performance
1M-6.86%
3M-13.64%
6M-18.10%
1Y-51.53%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

No notable strengths flagged.

CONS

  • Trading 58.1% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-
Industry PE
-
Forward P/E
-
PEG Ratio
-
Book Value
$-
Price to Book
-
P/S
-
EV/EBITDA
-
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-
Profit 5Y
-
Revenue (YoY)
-100.00%
Earnings (YoY)
-

Profitability & Returns

ROCE
-
ROE
-
ROA
-
Profit Margin
-
Op Margin
-
Gross Margin
-
EPS (Latest Qtr)
$-0.21
EPS (TTM)
$-

Balance Sheet & Liquidity

Debt/Equity
-
Quick Ratio
-
Current Ratio
-
Debt
-
Total Assets
$1.71M
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
23.53%
Chg in Prom Hold
-
FII / Inst Holding
5.49%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
-
Total Revenue (TTM)
$0
EBITDA
-
Free Cash Flow
$-7.44M
Operating Cash Flow
$-7.44M
Shares Outstanding
-
Gross Margin
-
Payout Ratio
-
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2013Jun 2013Sep 2013Mar 2014Jun 2014Sep 2014Mar 2015Jun 2015Sep 2015Mar 2016Jun 2016Sep 2016Mar 2017Jun 2017Sep 2017Mar 2018Jun 2018Sep 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026
Revenue ---------178.00K144.00K117.00K137.00K112.00K130.00K-------------------------
Gross Profit 38.00K69.00K--------------------------------------
Operating Income -26.00K6.00K26.00K63.00K65.00K42.00K75.00K72.00K83.00K-1.08M-1.38M-1.68M-2.88M-2.97M-3.04M-3.62M-3.25M-3.57M-3.69M-3.76M-3.23M-4.61M-3.57M-3.85M-2.97M-3.49M-2.71M-3.33M-2.50M-3.06M-3.51M-3.45M-2.60M-2.27M-1.65M-1.76M-2.73M-2.05M-1.49M-2.27M
Net Income -25.00K9.00K30.00K64.00K66.00K43.00K76.00K73.00K83.00K-1.50M-1.98M-3.25M-2.88M-2.94M-3.00M-3.58M-3.22M-3.54M-3.67M-3.75M-3.79M-4.59M-3.57M-3.85M-2.97M-3.49M-2.71M-3.33M-2.50M-3.06M-3.50M-3.42M-2.57M-2.27M-1.65M-1.74M-2.71M-2.05M-1.48M-2.26M
Diluted EPS -------------------------------------0.59---0.21
R&D Expense ---------441.00K497.00K684.00K1.03M1.29M1.70M1.96M2.03M2.26M2.17M2.22M2.01M2.79M2.22M2.47M1.84M2.36M2.24M2.19M2.30M2.14M2.38M2.31M1.87M1.24M800.00K931.00K1.53M1.37M936.00K1.24M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 012.00K---904.00K576.00K479.00K625.00K710.00K145.00K1.01M1.35M477.00K58.00K0
Gross Profit 012.00K62.00K-------------
Operating Income -583.00K-618.00K-339.00K9.00K231.00K-5.41M-7.61M-12.40M-14.10M-14.21M-15.53M-12.63M-11.90M-11.64M-8.00M-8.28M
Net Income -11.51M9.66M305.00K19.00K234.00K-6.70M-10.31M-12.31M-13.99M-14.71M-15.00M-12.62M-11.91M-11.57M-7.95M-8.23M
R&D Expense -----1.52M3.33M5.80M8.45M8.56M9.81M8.56M8.83M7.73M4.39M4.96M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Sep 2012Dec 2012Dec 2013Dec 2014Dec 2015Oct 2016Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets -5.43M13.73M-13.30M13.54M13.88M4.86M-22.08M13.54M6.42M7.68M23.42M15.72M9.79M2.99M3.72M3.41M
Total Equity 14.74M3.28M12.98M-13.29M13.31M-43.12M-3.44M-20.58M11.12M3.79M2.37M19.18M10.38M4.89M-1.60M837.00K895.00K
Cash & Equivalents 4.97M127.00K12.68M12.82M13.27M13.29M3.18M3.56M24.00M21.35M12.69M5.36M5.58M21.41M12.87M7.36M1.10M2.37M2.50M
Total Liabilities -2.16M756.00K-12.00K1.00K10.00K8.30M-1.50M2.41M2.62M5.31M4.25M5.34M4.90M4.59M2.89M2.52M
Current Liabilities -------8.30M-1.44M2.33M2.55M4.00M4.25M3.71M3.58M3.61M2.32M2.43M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -4.28M-3.09M-310.00K27.00K-7.02M-5.52M-8.67M-11.07M-9.45M-12.36M-10.37M-10.56M-9.97M-7.89M-7.44M
Investing Cash Flow -1.07M16.14M900.00K0-125.00K18.92M-136.00K-66.00K-146.00K-32.00K-116.00K-70.00K-12.00K-6.00K-7.00K
Financing Cash Flow 500.00K-500.00K0-7.52M4.40M144.00K3.80M9.82M28.21M1.95M5.12M3.73M9.16M7.57M
Capital Expenditure -1.07M-137.00K-0--125.00K--136.00K-66.00K-146.00K-32.00K-116.00K-70.00K-12.00K-6.00K-7.00K
Free Cash Flow -5.35M-3.22M-310.00K--7.15M--8.81M-11.13M-9.59M-12.39M-10.48M-10.63M-9.99M-7.89M-7.44M

Ratios (Annual)

Figures in %.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -100.0%--------------
Operating Margin % --5,150.0%----598.3%-1,320.8%-2,589.8%-2,256.3%-2,001.8%-10,709.7%-1,244.3%-880.3%-2,441.1%-13,794.8%-
Net Margin % -80,516.7%----740.8%-1,789.9%-2,569.5%-2,237.9%-2,071.7%-10,347.6%-1,243.6%-880.7%-2,425.8%-13,700.0%-
ROE % -351.0%74.4%2.3%0.1%-0.5%194.6%-50.1%-110.6%-368.9%-620.6%-78.2%-121.7%-243.4%721.8%-949.3%-919.3%
ROCE % -----157.1%-36.9%-110.7%-364.5%-386.7%-81.0%-105.2%-191.7%1,875.0%-570.3%-843.8%

Shareholding Pattern

Insiders
23.53%
Institutions
5.49%
Public Float
7.18%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for BCDA

Yahoo Finance Wed, 05 Aug 2026

BioCardia to Host Q2 2026 Financial Results and Corporate Update Conference Call on August 12, 2026

SUNNYVALE, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corpora…

Yahoo Finance ue, 28 Jul 2026

Congestive Heart Failure Market to Register Immense Growth at a CAGR of 8% During the Forecast Period (2026-2036) | DelveInsight

Recently published Congestive Heart Failure Market Insights report includes a comprehensive understanding of current treatment practices, congestive heart failure emerging drugs, market share of individual therapies, and current and forecas…

Yahoo Finance ue, 14 Jul 2026

New Strong Sell Stocks for July 14th

AZ, AISP and BCDA have been added to the Zacks Rank #5 (Strong Sell) List on July 14th, 2026.

Yahoo Finance hu, 18 Jun 2026

BioCardia Letter to Stockholders on 2026 Priorities and Strategic Opportunities

SUNNYVALE, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that the Company’s C…

Yahoo Finance Mon, 08 Jun 2026

BioCardia Announces $4.4 Million Financing

Net proceeds anticipated to extend cash runway into first quarter of 2027 beyond expected Japan PMDA submission; if currently outstanding warrants issued in previous financings are exercised in full for cash, it is anticipated that the cash…

Yahoo Finance Fri, 05 Jun 2026

Sector Update: Healthcare Stocks Higher Late Afternoon

Healthcare stocks rose late Friday afternoon with the NYSE Healthcare Index increasing 0.6% and the

BCDA — Frequently Asked Questions

What is the current share price of BCDA?

As of 2026-08-05 17:25 PDT, BCDA trades at $0.95 on NASDAQ/NYSE. Its 52-week range is $0.77 to $2.27.

Is BCDA a good stock to buy?

This page provides a data-driven analysis of BCDA, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space